Show simple item record

dc.contributor.authorMcIntyre, I G
dc.contributor.authorSpreckley, Katherine
dc.contributor.authorClarke, Robert B
dc.contributor.authorAnderson, Elizabeth
dc.contributor.authorClarke, Noel W
dc.contributor.authorGeorge, N J
dc.date.accessioned2009-11-23T12:12:19Z
dc.date.available2009-11-23T12:12:19Z
dc.date.issued2000-10
dc.identifier.citationOptimization of the reverse transcriptase polymerase chain reaction for the detection of circulating prostate cells. 2000, 83 (8):992-7 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid10993644
dc.identifier.doi10.1054/bjoc.2000.1417
dc.identifier.urihttp://hdl.handle.net/10541/86671
dc.description.abstractThe reverse transcriptase polymerase chain reaction (RT-PCR) is a sensitive technique that can detect prostate-specific messenger RNA in circulating blood. Many authors have studied the potential of RT-PCR as a staging technique in prostate cancer (PC). Clinical sensitivity and in some cases specificity has been disappointing. Few authors have been able to correlate RT-PCR result with patient stage. We have compared the results of using two different RT-PCR protocols with different sensitivities on blood samples from prostate cancer patients. An 80-amplification-cycle nested primer RT-PCR assay had a detection limit of 10 prostate cells and a 50-cycle RT-PCR could detect 20 cells in 5 ml blood. The 80-cycle assay detected prostate mRNA in four of 10 female samples, whereas the 50-cycle assay detected it in none. There was little difference in the assays' ability to detect prostate mRNA in advanced PC patients. The 50-cycle assay could differentiate between hormone-escaped, stable hormone-treated and untreated localized PC patients, whereas the 80-cycle assay could not. Each blood sample must be assayed several times with RT-PCR to avoid false-negative results and, if this is done, assay specificity can be increased with little effect on clinical sensitivity.
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subjectProstatic Canceren
dc.subject.meshFalse Negative Reactions
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshNeoplasm Staging
dc.subject.meshPolymerase Chain Reaction
dc.subject.meshProstate-Specific Antigen
dc.subject.meshProstatic Neoplasms
dc.subject.meshRNA, Messenger
dc.subject.meshReference Values
dc.subject.meshReproducibility of Results
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction
dc.subject.meshSensitivity and Specificity
dc.titleOptimization of the reverse transcriptase polymerase chain reaction for the detection of circulating prostate cells.en
dc.typeArticleen
dc.contributor.departmentDepartment of Urology, Withington Hospital, Manchester, M21 1AH, UK.en
dc.identifier.journalBritish Journal of Canceren
refterms.dateFOA2020-04-21T14:52:08Z
html.description.abstractThe reverse transcriptase polymerase chain reaction (RT-PCR) is a sensitive technique that can detect prostate-specific messenger RNA in circulating blood. Many authors have studied the potential of RT-PCR as a staging technique in prostate cancer (PC). Clinical sensitivity and in some cases specificity has been disappointing. Few authors have been able to correlate RT-PCR result with patient stage. We have compared the results of using two different RT-PCR protocols with different sensitivities on blood samples from prostate cancer patients. An 80-amplification-cycle nested primer RT-PCR assay had a detection limit of 10 prostate cells and a 50-cycle RT-PCR could detect 20 cells in 5 ml blood. The 80-cycle assay detected prostate mRNA in four of 10 female samples, whereas the 50-cycle assay detected it in none. There was little difference in the assays' ability to detect prostate mRNA in advanced PC patients. The 50-cycle assay could differentiate between hormone-escaped, stable hormone-treated and untreated localized PC patients, whereas the 80-cycle assay could not. Each blood sample must be assayed several times with RT-PCR to avoid false-negative results and, if this is done, assay specificity can be increased with little effect on clinical sensitivity.


Files in this item

Thumbnail
Name:
91759.pdf
Size:
341.9Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record